A Phase 1 interventional study of Saline and EN3835 in Fibroids, Uterine and Leiomyoma, sponsored by Advance Biofactures Corporation. Completed at 1 site in United States. Open to female participants aged 35 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-07-10.
Sponsored by Advance Biofactures Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Leiomyoma with a site in United States — 20 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.
Among the 156 studies in Leiomyoma with a site in United States, this one is the 102nd largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2016, is one of 13 in phase 1, and was the 88th registered.
438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →20 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–50 · Women only
Zenchi, Inc. · Sites in United States
Ages 20–45 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
Johns Hopkins University · Sites in United States
Ages 18+ · Women only
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 35 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 21 · Phase 3 32 · Phase 4 17
First in 1995; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 66 across 306 interventional studies indexed under Leiomyoma.
Median enrollment 57 across the 121 interventional studies, 187 across the 34 observational. Of the 113 that completed or were terminated, 59 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 156 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Advance Biofactures Corporation as lead sponsor.
Advance Biofactures Corporation has 1 study filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
8 of the studies in Leiomyoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07286188Northwestern UniversityEffect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | 2026-12 |
| NCT06536517Johns Hopkins UniversityThe Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | 2026-12 |
| NCT04126824University of California, Los AngelesEffect of Addition of Steroids on Duration of Analgesia | 2026-12-30 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
| NCT05739136Sumitomo Pharma Switzerland GmbHMYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 156 studies in Leiomyoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study evaluates the safety and tolerability of a single injection of collagenase enzyme directly into a uterine fibroid in subjects already selected for hysterectomy or myomectomy.
Fibroids contain excessive amounts of collagen and it is possible that digestion of collagen may be beneficial in reducing pain and bleeding associated with fibroids.
Three subjects will be injected with saline only to evaluate the safety and effectiveness of the injection method. Additional subjects will then be injected with increasing doses of study drug.
Collagenase enzyme breaks down collagen and has shown efficacy in clinical trials for a number of diseases for which there is an accumulation of collagen.
It is possible that lysis of collagen may reduce the collagen content of fibroids thus decreasing the size of fibroids, and possibly reducing the stiffness of fibroids. This may result in reducing the symptoms of pain and bleeding associated with fibroids.
In this study three subjects will be injected with saline only followed immediately by hysterectomy in order to evaluate the safety and effectiveness of the injection method.
Twelve subjects will receive a single injection of study drug as follows: three subjects will receive a set dose of collagenase enzyme followed by hysterectomy or myomectomy 24-96 hours later (Group 1) to evaluate safety of the injection of study drug. Nine subjects will then receive increasing doses of collagenase enzyme followed by hysterectomy or myomectomy 60-90 days later (Group 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection of saline to assess the injection procedure
Other: Saline
Injection of maximum marketed dose of EN3835 regardless of fibroid size
Drug: EN3835
Injection of 0.05 mg EN3835 per cm3 fibroid
Drug: EN3835
Injection of 0.1 mg EN3835 per cm3 fibroid
Drug: EN3835
Injection of 0.2 mg EN3835 per cm3 fibroid
Drug: EN3835
Saline injection
Comparison of maximum marketed dose and multiple doses EN3835
Also known as: Collagenase clostridium histolyticum
Number of participants with treatment-related adverse events following a single injection of EN3835 into a fibroid
Assessed by number of subjects with uterine injury or peritoneal irritation determined post hysterectomy
Time frame: Through hysterectomy or myomectomy (average = 60-90 days post injection)
Change in symptoms of pain and bleeding and quality of life
Determined by standardized questionnaires for menstrual distress, quality of life and sexual activity; McGill Pain Questionnaire
Time frame: Throughout the study prior to hysterectomy or myomectomy(avg 60-90 days post injection study drug)
Reduction in size of treated fibroids- Group 2
Size of fibroid to be determined post hysterectomy or myomectomy
Time frame: 60-90 days post injection study drug
Increased rate of apoptosis of treated fibroids -Group 2
Specimens to be taken post hysterectomy or myomectomy and evaluated by TUNEL staining
Time frame: 60-90 days post injection study drug
Reduction in collagen content of treated fibroids-Group 2
Specimens to be taken post hysterectomy or myomectomy and by tested histology stains
Time frame: 60-90 days post injection study drug
Reduction in stiffness of treated fibroid-Group 2
Specimens to be taken post hysterectomy or myomectomy and tested via rheometry
Time frame: 60-90 days post injection study drug
Plan to share: No
Ran from Oct 2016 to primary completion in Oct 2018, 23 months.
Of 13 phase 1 interventional studies under Leiomyoma, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 41. This study's 23 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase